Effects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose study
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.